Reviewing Global Cord Blood Corporation (CO)’s and Nightstar Therapeutics plc (NASDAQ:NITE)’s results

Both Global Cord Blood Corporation (NYSE:CO) and Nightstar Therapeutics plc (NASDAQ:NITE) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood Corporation N/A 0.00 N/A 0.28 26.39
Nightstar Therapeutics plc N/A 0.00 42.26M -1.93 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Global Cord Blood Corporation and Nightstar Therapeutics plc.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Global Cord Blood Corporation 0.00% 7.2% 3.8%
Nightstar Therapeutics plc 0.00% -38.7% -35.1%


Global Cord Blood Corporation has a Current Ratio of 9.7 and a Quick Ratio of 9.6. Competitively, Nightstar Therapeutics plc’s Current Ratio is 7.7 and has 7.7 Quick Ratio. Global Cord Blood Corporation’s better ability to pay short and long-term obligations than Nightstar Therapeutics plc.


The annual dividend that Global Cord Blood Corporation pay is $0.08 per share with a dividend yield of 1.09%. Nightstar Therapeutics plc does not offer a dividend.

Analyst Ratings

The following table given below contains the ratings and recommendations for Global Cord Blood Corporation and Nightstar Therapeutics plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Global Cord Blood Corporation 0 0 0 0.00
Nightstar Therapeutics plc 0 5 0 2.00

Competitively Nightstar Therapeutics plc has a consensus target price of $25.5, with potential downside of -0.08%.

Institutional & Insider Ownership

Roughly 17.4% of Global Cord Blood Corporation shares are held by institutional investors while 52.2% of Nightstar Therapeutics plc are owned by institutional investors. Insiders held roughly 49.6% of Global Cord Blood Corporation’s shares. On the other hand, insiders held about 3.1% of Nightstar Therapeutics plc’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Cord Blood Corporation 3.79% 17.68% 15.29% 6.79% -29.82% 14.57%
Nightstar Therapeutics plc 58.46% 84.74% 75.59% 24.04% 100.32% 118.58%

For the past year Global Cord Blood Corporation has weaker performance than Nightstar Therapeutics plc


Global Cord Blood Corporation beats on 7 of the 9 factors Nightstar Therapeutics plc.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.